Insulin-degrading enzyme inhibition, a novel therapy for type 2 diabetes?
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 25100059.
- Also identified by DOI 10.1016/j.cmet.2014.07.016 and PMC identifier 4144405.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The insulin-degrading enzyme (IDE) has been identified as a type 2 diabetes and Alzheimer's disease susceptibility gene, though its physiological function remains unclear. Maianti et al. (2014) now propose that an IDE inhibitor may be a promising therapeutic strategy for type 2 diabetes.
Medical subject headings
- Glucagon
- Hypoglycemic Agents
- Insulin
- Insulysin
- Islet Amyloid Polypeptide
- Macrocyclic Compounds